• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Research Brief on Ethyl 2-(1-Aminocyclopentyl)acetate (CAS: 112823-05-9) in Chemical Biology and Pharmaceutical Applications

Ethyl 2-(1-Aminocyclopentyl)acetate (CAS: 112823-05-9) is a cyclopentyl-based compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, including peptidomimetics, enzyme inhibitors, and novel drug candidates. The unique structural features of Ethyl 2-(1-Aminocyclopentyl)acetate, such as its cyclopentyl ring and ester functionality, make it a valuable building block for medicinal chemistry and drug discovery programs.

Recent studies have explored the synthetic utility of Ethyl 2-(1-Aminocyclopentyl)acetate in the development of protease inhibitors and G-protein-coupled receptor (GPCR) modulators. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its use as a precursor for the synthesis of novel cathepsin K inhibitors, which show promise for treating osteoporosis and bone metastasis. The researchers highlighted the compound's ability to introduce conformational constraints in peptide-based inhibitors, thereby enhancing their metabolic stability and target selectivity.

In neuropharmacology, Ethyl 2-(1-Aminocyclopentyl)acetate has been investigated as a scaffold for developing modulators of neurotransmitter systems. A recent study published in ACS Chemical Neuroscience (2024) reported its incorporation into novel dopamine D3 receptor-selective ligands. The cyclopentyl moiety was found to contribute significantly to receptor subtype selectivity, potentially reducing off-target effects in the treatment of Parkinson's disease and schizophrenia.

The compound's pharmacokinetic properties have also been a subject of investigation. Research published in European Journal of Pharmaceutical Sciences (2023) examined the metabolic stability and membrane permeability of Ethyl 2-(1-Aminocyclopentyl)acetate derivatives. The studies revealed that the ester group provides favorable properties for prodrug development, with controlled hydrolysis rates that can be modulated through structural modifications of the cyclopentyl ring.

From a synthetic chemistry perspective, recent advances in asymmetric synthesis have improved access to enantiomerically pure forms of Ethyl 2-(1-Aminocyclopentyl)acetate. A 2024 Nature Communications paper described a biocatalytic approach using engineered aminotransferases to produce the (R)-enantiomer with >99% ee, which is particularly valuable for chiral drug development. This methodological breakthrough addresses previous challenges in obtaining stereochemically pure forms of this important building block.

Looking forward, Ethyl 2-(1-Aminocyclopentyl)acetate continues to show promise in multiple therapeutic areas. Current research directions include its application in the development of antiviral agents, particularly against SARS-CoV-2 proteases, and as a component of targeted protein degraders (PROTACs). The compound's versatility and the growing body of research supporting its utility suggest it will remain an important tool in medicinal chemistry and drug discovery efforts for years to come.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)